BCLSI
CABA icon

Bain Capital Life Sciences Investors’s Cabaletta Bio CABA Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26M Hold
9,677,125
– – 2.35% 11
2025
Q4 		$21.2M Hold
9,677,125
– – 1.62% 13
2025
Q3 		$22.6M Hold
9,677,125
– – 1.5% 12
2025
Q2 		$14.7M Buy
9,677,125
+6,916,237
+251% +$10.8M 1.84% 12
2025
Q1 		$3.82M Hold
2,760,888
– – 0.57% 16
2024
Q4 		$6.27M Hold
2,760,888
– – 0.74% 18
2024
Q3 		$13M Buy
2,760,888
+1,110,924
+67% +$6.43M 1.36% 12
2024
Q2 		$12.3M Buy
1,649,964
+32,600
+2% +$400K 1.36% 14
2024
Q1 		$27.6M Sell
1,617,364
-382,636
-19% -$8.21M 2.22% 12
2023
Q4 		$45.4M Hold
2,000,000
– – 4.35% 7
2023
Q3 		$30.4M Hold
2,000,000
– – 3.4% 10
2023
Q2 		$25.8M Buy
+2,000,000
New +$21.7M 2.66% 15

Other funds holding CABA

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bain Capital Life Sciences Investors's CABA Position: Q1 2026 in Review

Bain Capital Life Sciences Investors held its Cabaletta Bio (CABA) position steady in Q1 2026 at 9,677,125 shares worth $26M. The position accounts for 2.35% of the portfolio, ranked #11.

Bain Capital Life Sciences Investors first reported a position in CABA in Q2 2023 and has held it in 12 quarters since. The position peaked at $45.4M in Q4 2023. 108 funds tracked by Wall St. Rank hold CABA as of Q1 2026.

  • Bain Capital Life Sciences Investors held 9,677,125 shares of Cabaletta Bio worth $26M as of Q1 2026.
  • Bain Capital Life Sciences Investors left its Cabaletta Bio share count unchanged in Q1 2026.
  • Cabaletta Bio made up 2.35% of Bain Capital Life Sciences Investors's portfolio in Q1 2026, its #11 holding.
  • Bain Capital Life Sciences Investors first reported a position in Cabaletta Bio in Q2 2023 and has held it in 12 quarters since.
  • Bain Capital Life Sciences Investors's Cabaletta Bio position peaked at $45.4M in Q4 2023.
  • 108 funds tracked by Wall St. Rank held Cabaletta Bio as of Q1 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2026, filed 15 May 2026.